Cloudbreak Pharma Announces Results of First-of-Its-Kind Patient Survey on Pinguecula, Confirming Significant Unmet Need and Impact on Quality of Life

IRVINE, Calif.--(BUSINESS WIRE)--Cloudbreak Pharma Inc., (HKEX 2592), a clinical stage ophthalmic drug company leveraging its proprietary Multi Kinase Inhibitor (MKI) discovery platform to develop first-in-class and best-in-class therapeutics, today announced the results of a comprehensive market research survey examining the experience of patients diagnosed with pinguecula and assessing their interest in a new pharmaceutical treatment option. The survey was conducted by an independent, third-p